GBS Inc. GBS
Set alert
At close
52-week range unavailable
- Open
- 0.4808
- Prev close
- 0.4732
- Mkt cap
- 7.05M
- Vol
- 9.03K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.4507
- High
- 0.4854
- Forward P/E
- -5.26
- Beta
- 0.00
- Short ratio
- 1.84
- Inst. own
- 2.79%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 31, 2022
- 50-d avg
- 0.49918
- 200-d avg
- 0.69182
- 1y target
- 4.50
Key statistics
- Market cap
- 7.05M
- Enterprise value
- -1.32M
- Trailing P/E
- 0.00
- Forward P/E
- -5.26
- PEG ratio
- 0.00
- Price / sales
- 16.12
- Price / book
- 1.06
- EPS (TTM)
- -0.502
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 437.15K
- Revenue growth
- -95.80%
- Free cash flow
- -1.56M
- Total cash
- 8.28M
- Total debt
- 0
- Return on equity
- -77.34%
- Shares outstanding
- 14.89M
- Short % of float
- 1.02%
- 50-day average
- 0.49918
- 200-day average
- 0.69182
Analyst view
Consensus: none
Next earnings
Aug 31, 2022
Expected Aug 31, 2022. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 31, 2022 | Jun 1, 2022 | -0.18 | — | — | — |
| May 10, 2022 | Mar 1, 2022 | -0.16 | — | — | — |
| Feb 10, 2022 | Dec 1, 2021 | -0.16 | — | — | — |
| Nov 11, 2021 | Sep 1, 2021 | 0.00 | — | — | — |
| May 14, 2021 | Mar 1, 2021 | 0.00 | — | — | — |
About GBS Inc.
GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- gbs.inc
News
- Intuit (INTU) Reports Strong Q4 but Cautious FY27 Guidance Raises Concerns
- Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia
- Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation
- Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
- Is Intuit (INTU) Undervalued After Q3 FY26 Earnings? EPS $11.09 Beats Estimates, Revenue $8.56B Misses; GF Score 87/100, 51.2% Undervalued
- Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
- 110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS
- Larry Robbins Increases Stake in DXC Technology Co
- Kimberly-Clark Appoints Francesco Tinto as Chief Information & GBS Officer
- Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
Your note
Sign in to keep a note on GBS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOYAGES STEVEN CONSTANTINE | Chief Executive Officer | Stock Award(Grant) | Oct 9, 2022 | 75,000 |
| FISHER LAWRENCE B | Director | Stock Award(Grant) | Oct 9, 2022 | 15,000 |
| GAVRILENKO VICTORIA | Director | Purchase | Mar 1, 2021 | 37 |
| HURD JONATHAN S | Director | Stock Award(Grant) | Oct 9, 2022 | 15,000 |
| LIFE SCIENCE BIOSENSOR DIAGNOSTICS PTY, LTD. | Unknown | Sale | Feb 16, 2022 | 1,081,800 |
| MARGELIS GEORGE | Director | Stock Award(Grant) | Oct 9, 2022 | 15,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.78% | 115,825 | 54.81K | Jun 29, 2022 |
| Renaissance Technologies, LLC | 0.75% | 111,900 | 52.95K | Jun 29, 2022 |
| State Street Corporation | 0.23% | 34,115 | 16.14K | Jun 29, 2022 |
| Susquehanna International Group, LLP | 0.23% | 33,695 | 15.94K | Jun 29, 2022 |
| HRT Financial LP | 0.14% | 20,568 | 9.73K | Jun 29, 2022 |
| IHT Wealth Management, LLC | 0.13% | 20,000 | 9.46K | Jun 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.76% | 113,118 | 53.53K | Jun 29, 2022 |
| Vanguard Extended Market Index Fund | 0.08% | 11,388 | 5.39K | Jun 29, 2022 |